As an infrastructure at the German Center for Infection Research (DZIF), the Clinical Trial Unit tracks DZIF's study activities in the “Healex Site Management System (SMS)”. Studies are sorted by indication and are continuously updated.
The study register has recently been expanded to include the category “COVID-19”. For the first time, not only DZIF study activities are presented here: In order to provide a comprehensive overview in the current pandemic situation of planned and already active COVID-19 studies in Germany, the Clinical Trial Unit is cooperating with researchers from various German Centers for Health Research and other networks.
- Overall Study
- Study Sites (1)
|PMOS GERM 07-11|
Purpose / Objectives
To assess the tolerability of lopinavir/r in combination with a Integrase Inhibitor
To characterize the development of resistance.
To assess the development of CD4 cell count.
HIV-1 infected patients
Patients that will be treated with Kaletra, independent from their participation in this study
Patients that will be treated with an Integrase Inhibitor, independent from their participation in this study
The exclusion criteria are as stated in the German Summary of Product Characteristics (SPC) for Kaletra (Appendix I) and Integrase Inhibitors (Appendix II)